Feb 6 (Reuters) - Cyclopharm Ltd (CYC)
- Confirms it remains on track to record initial sales of ultralutetm in first half of 2017
- Expects to report record sales revenue for 2016 full year of $14.4 million and underlying EBITDA of approximately $3.4 million
News: CYC Cyclopharm expects FY16 underlying EBITDA of about $3.4 mln
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
0.030(3.02%) |
Mkt cap ! $113.9M | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.04 | $1.00 | $103.0K | 100.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 11798 | $1.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 5000 | 1 |
View Market Depth
| Last trade - 13.21pm 17/06/2025 (20 minute delay) ? |
| CYC (ASX) Chart |